Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)

Purpose Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause. Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with ado-trastuzumab emtansine (T-DM1). Methods Patients with T1N0 HER2 + early-stage br...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2021-08, Vol.189 (1), p.103-110
Hauptverfasser: Ruddy, Kathryn J., Zheng, Yue, Tayob, Nabihah, Hu, Jiani, Dang, Chau T., Yardley, Denise A., Isakoff, Steven J., Valero, Vicente V., Faggen, Meredith G., Mulvey, Therese M., Bose, Ron, Sella, Tal, Weckstein, Douglas J., Wolff, Antonio C., Reeder-Hayes, Katherine E., Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan S., Hart, Lowell L., Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit L., Briccetti, Frederick M., Schneider, Bryan P., Merrill Garrett, A., Kelly Marcom, P., Albain, Kathy S., DeFusco, Patricia A., Tung, Nadine M., Ardman, Blair M., Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta C., Rosenberg, Shoshana, DeMeo, Michelle K., Burstein, Harold J., Winer, Eric P., Krop, Ian E., Partridge, Ann H., Tolaney, Sara M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Chemotherapy-related amenorrhea (CRA) is a surrogate for ovarian toxicity and associated risk of infertility and premature menopause. Here, we compare CRA rate with paclitaxel (T)-trastuzumab (H) to that with ado-trastuzumab emtansine (T-DM1). Methods Patients with T1N0 HER2 + early-stage breast cancer (eBC) enrolled on the ATEMPT trial and were randomized 3:1 to T-DM1 3.6 mg/kg IV every (q) 3 weeks (w) × 17 vs. T 80 mg/m 2 with H IV qw × 12 (4 mg/kg load → 2 mg/kg), followed by H (6 mg/kg IV q3w × 13). Enrollees who self-reported as premenopausal were asked to complete menstrual surveys at baseline and every 6–12 months for 60 months. 18-month CRA (no periods reported during prior 6 months on 18-month survey) was the primary endpoint of this analysis. Results Of 512 ATEMPT enrollees, 123 who began protocol therapy and answered baseline and at least one follow-up menstrual survey were premenopausal at enrollment. 76 had menstrual data available at 18 months without having received a gonadotropin-releasing hormone agonist or undergone hysterectomy and/or oophorectomy. Median age was 45 (range 23–53) among 18 who had received TH and 46 (range 34–54) among 58 who had received T-DM1. The 18-month rate of CRA was 50% after TH and 24% after T-DM1 ( p  = 0.045). Conclusion Amenorrhea at 18 months was less likely in recipients of adjuvant T-DM1 than TH. Future studies are needed to understand how T-DM1 impacts risk of infertility and permanent menopause, and to assess amenorrhea rates when T-DM1 is administered after standard HER2-directed chemotherapy regimens.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-021-06267-8